AXIM — AXIM BIOTECHNOLOGIES, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1514946 ·
Last close
$0.01
Market Cap
$1.80M
52W High
$0.01
52W Low
$0.00
ADV30
168,827
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | 0 | -21,656 | 370,171 | — | 2,803 | — |
| Mar 2025 | 0 | 0 | -268,739 | -234,253 | 3,346,106 | 7,184 | 13,983,424 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-806,651
Investing CF
$0
Financing CF
$1,338,418
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,931,577
Inventory
$0
Receivables
—
ST Investments
—
EBIT TTM
$220,218
Pretax Income TTM
$135,918
Interest Exp TTM
$84,300
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$92,898
EBITDA
$-1,883,836
Free Cash Flow
$-2,999,857
Enterprise Value
$8,513,028
Total Cash
$6,044
Total Debt
$6,782,759
Shares Out
340,456,626
Trailing EPS
$0.00
Book Value
$-0.03
ROE
—
ROA
-36.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 70,458 | -1,763,079 | -3,520,471 | 3,447,296 | 13,866,861 | — | -855,058 |
| Dec 2023 | 39,518 | -2,750,839 | -8,059,682 | 4,121,548 | 11,778,195 | — | -1,030,500 |
| Dec 2022 | 8,875 | -4,652,772 | -6,242,949 | 4,212,035 | 9,037,447 | — | -2,044,326 |
| Dec 2021 | 60,460 | -7,728,565 | -16,032,305 | 5,323,435 | 7,661,635 | — | -2,486,765 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UPC | Universe Pharmaceuticals INC | $1.65M | $2.61 | — |
| CLSDQ | Clearside Biomedical, Inc. | $1.65M | $0.31 | — |
| BSPK | Bespoke Extracts, Inc. | $1.98M | $0.18 | — |
| PCYN | PROCYON CORP | $1.64M | $0.20 | — |
| JAGX | Jaguar Health, Inc. | $1.60M | $3.11 | — |
News headlines (Yahoo Finance, 1h cache)
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
2026-01-29 14:00 · Yahoo
Medical Marijuana, Inc. and AXIM Biotechnologies, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
2026-01-29 14:00 · Yahoo
AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
2026-01-20 14:00 · Yahoo
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
2025-10-23 12:00 · Yahoo
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
2025-10-07 13:01 · Yahoo
Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
2025-06-24 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.